Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations

Breast Cancer Research and Treatment
Katherine CliftonBanu Arun

Abstract

As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflicting results in overall survival in patients receiving neoadjuvant or adjuvant systemic therapy. This study aims to analyze outcomes of adjuvant versus neoadjuvant in patients with early-stage triple-negative breast cancer with and without BRCA germline mutations. Patients with stage I or II triple-negative breast cancer who had BRCA testing were identified from a prospective cohort study of 4027 patients. Clinical, demographic, genetic test results, chemotherapy, recurrence, and survival data were analyzed. Overall survival and disease-free survival were estimated using the Kaplan-Meier method. 319 patients with stage I and II triple-negative breast cancer who met eligibility criteria were included in the analysis. 187 received adjuvant chemotherapy (58.6%) and 132 received neoadjuvant chemotherapy (41.4%). 135 were BRCA positive (42.3%) and 184 were BRCA negative (57.7%). There was no significant association between overall survival or disease-free survival and treatment with neoadjuvant ve...Continue Reading

References

Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
Jul 6, 2010·The Journal of Surgical Research·Carlie R KennedyJulie A Margenthaler
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Janice S KwonBanu Arun
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Banu ArunConstance Albarracin
Jun 6, 2012·PloS One·Peter MeyerBeyhan Ataseven
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Mar 31, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George SomloJeffrey N Weitzel
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte

❮ Previous
Next ❯

Citations

Nov 21, 2019·International Journal of Cancer. Journal International Du Cancer·Wolfgang S LiebAngelika Hausser
Sep 10, 2019·Tumori·Lucia MangonePaolo Giorgi Rossi
May 19, 2020·The Journal of Surgical Research·Trista J Stankowski-DrenglerHeather B Neuman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.